Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo

Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo Griffithsin (GRFT) is a broad-spectrum antiviral protein that is effective against several glycosylated viruses. Here, we have evaluated the in vitro and in vivo antiviral activities of GRFT against Japanese encephalitis virus (JEV) infection. In vitro experiments showed that treatment of JEV with GRFT before inoculation of BHK-21 cells inhibited infection in a dose-dependent manner, with 99 % inhibition at 100 μg/ml and a 50 % inhibitory concentration ( IC 50 ) of 265 ng/ml (20 nM). Binding assays suggested that binding of GRFT to JEV virions inhibited JEV infection. In vivo experiment showed that GRFT (5 mg/kg) administered intraperitoneally before virus infection could completely prevent mortality in mice challenged intraperitoneally with a lethal dose of JEV. Our study also suggested that GRFT prevents JEV infection at the entry phase by targeting the virus. Collectively, our data demonstrate that GRFT is an antiviral agent with potential application in the development of therapeutics against JEV or other flavivirus infections. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Virology Springer Journals

Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo

Download PDF
10 pages
Read Article

Loading next page...
 
/lp/springer_journal/griffithsin-inhibits-japanese-encephalitis-virus-infection-in-vitro-8tj42U4ags
Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Biomedicine; Virology; Medical Microbiology; Infectious Diseases
ISSN
0304-8608
eISSN
1432-8798
DOI
10.1007/s00705-012-1489-2
pmid
23053519
Publisher site
See Article on Publisher Site

Abstract

Griffithsin (GRFT) is a broad-spectrum antiviral protein that is effective against several glycosylated viruses. Here, we have evaluated the in vitro and in vivo antiviral activities of GRFT against Japanese encephalitis virus (JEV) infection. In vitro experiments showed that treatment of JEV with GRFT before inoculation of BHK-21 cells inhibited infection in a dose-dependent manner, with 99 % inhibition at 100 μg/ml and a 50 % inhibitory concentration ( IC 50 ) of 265 ng/ml (20 nM). Binding assays suggested that binding of GRFT to JEV virions inhibited JEV infection. In vivo experiment showed that GRFT (5 mg/kg) administered intraperitoneally before virus infection could completely prevent mortality in mice challenged intraperitoneally with a lethal dose of JEV. Our study also suggested that GRFT prevents JEV infection at the entry phase by targeting the virus. Collectively, our data demonstrate that GRFT is an antiviral agent with potential application in the development of therapeutics against JEV or other flavivirus infections.

Journal

Archives of Virology – Springer Journals

Published: Feb 1, 2013

References

  • Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology: glycan-dependent gp120/protein interactions
    Adams, EW; Ratner, DM; Bokesch, HR; McMahon, JB; O’Keefe, BR; Seeberger, PH
  • Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site
    Alexandre, KB; Gray, ES; Pantophlet, R; Moore, PL; McMahon, JB; Chakauya, E; O’Keefe, BR; Chikwamba, R; Morris, L
  • Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy
    Balzarini, J
  • Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner
    Bolmstedt, AJ; O’Keefe, BR; Shenoy, SR; McMahon, JB; Boyd, MR
  • From the World Health Organization: development of dengue and Japanese encephalitis vaccines
    Brandt, WE
  • Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation
    Bressanelli, S; Stiasny, K; Allison, SL; Stura, EA; Duquerroy, S; Lescar, J; Heinz, FX; Rey, FA
  • De novo synthesis, constitutive expression of Aspergillus sulphureus β-xylanase gene in Pichia pastoris and partial enzymic characterization
    Cao, Y; Qiao, J; Li, Y; Lu, W
  • Inhibition of Japanese encephalitis virus infection by the sulfated polysaccharides extracts from Ulva lactuca
    Chiu, YH; Chan, Y-L; Li, T-L; Wu, CJ
  • Japanese encephalitis: pathogenesis, prophylactics and therapeutics
    Dutta, K; Rangarajan, PN; Vrati, S; Basu, A
  • Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide
    Emau, P; Tian, B; O’keefe, B; Mori, T; McMahon, J; Palmer, K; Jiang, Y; Bekele, G; Tsai, C
  • Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture
    Giomarelli, B; Schumacher, KM; Taylor, TE; Sowder, RC; Hartley, JL; McMahon, JB; Mori, T
  • Studies of Japanese encephalitis in China
    Huang, C
  • A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice
    Kim, JM; Yun, SI; Song, BH; Hahn, YS; Lee, CH; Oh, HW; Lee, YM
  • Fields virology
    Lindenbach, BD; Thiel, H-Ju; Rice, CM
  • Griffithsin has antiviral activity against hepatitis C virus
    Meuleman, P; Albecka, A; Belouzard, S; Vercauteren, K; Verhoye, L; Wychowski, C; Leroux-Roels, G; Palmer, KE; Dubuisson, J
  • Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp
    Mori, T; O’Keefe, BR; Sowder, RC; Bringans, S; Gardella, R; Berg, S; Cochran, P; Turpin, JA; Buckheit, RW; McMahon, JB; Boyd, MR
  • Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component
    O’Keefe, BR; Vojdani, F; Buffa, V; Shattock, RJ; Montefiori, DC; Bakke, J; Mirsalis, J; d’Andrea, AL; Hume, SD; Bratcher, B
  • Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae
    O’Keefe, BR; Giomarelli, B; Barnard, DL; Shenoy, SR; Chan, PKS; McMahon, JB; Palmer, KE; Barnett, BW; Meyerholz, DK; Wohlford-Lenane, CL
  • A simple method of estimating fifty per cent endpoints
    Reed, LJ; Muench, H
  • Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods
    Schmittgen, TD; Zakrajsek, BA; Mills, AG; Gorn, V; Singer, MJ; Reed, MW
  • N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo
    Sebastian, L; Desai, A; Shampur, MN; Perumal, Y; Sriram, D; Vasanthapuram, R
  • Pentoxifylline inhibits replication of Japanese encephalitis virus: a comparative study with ribavirin
    Sebastian, L; Desai, A; Madhusudana, SN; Ravi, V
  • Complete nucleotide sequence of the Japanese encephalitis virus genome RNA
    Sumiyoshi, H; Mori, C; Fuke, I; Morita, K; Kuhara, S; Kondou, J; Kikuchi, Y; Nagamatu, H; Igarashi, A
  • Development and validation of Real-Time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytesin vitro
    Winer, J; Jung, CKS; Shackel, I; Williams, PM
  • Regulation of Vid-dependent degradation of FBPase by TCO89, a component of TOR Complex 1
    Yan, Y; Kang, B
  • Japanese encephalitis virus infection induces changes of mRNA profile of mouse spleen and brain
    Yang, Y; Ye, J; Yang, X; Jiang, R; Chen, H; Cao, S
  • Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding
    Ziolkowska, NE; O’Keefe, BR; Mori, T; Zhu, C; Giomarelli, B; Vojdani, F; Palmer, KE; McMahon, JB; Wlodawer, A
  • Structural studies of algal lectins with anti-HIV activity
    Ziółkowska, NE; Wlodawer, A